Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Genomma Lab Internacional, S.A.B. de C.V. is a Mexico‑based consumer healthcare and personal care company focused on the development, marketing, and commercialization of branded products. The company operates primarily in the over‑the‑counter (OTC) pharmaceuticals, personal care, dermocosmetics, and food and beverage supplements industries, targeting mass‑market consumers through high‑volume retail channels. Its revenue is driven by a diversified portfolio of proprietary brands positioned in self‑care, beauty, hygiene, and everyday wellness categories.
The company is known for its asset‑light operating model, emphasizing brand creation, advertising, and distribution rather than in‑house manufacturing. Genomma Lab was founded in 1996 in Mexico and grew rapidly in the 2000s by leveraging intensive direct‑to‑consumer advertising and fast product launches. Over time, it expanded internationally and consolidated its position as one of the leading consumer health companies in Latin America, while also establishing a presence in the United States and select European markets.
Business Operations
Genomma Lab organizes its business primarily around two core segments: Pharmaceuticals and Personal Care and Nutrition. The Pharmaceuticals segment includes OTC medicines for cough, cold, pain relief, gastrointestinal health, and dermatological treatments, while the Personal Care and Nutrition segment encompasses hair care, skin care, oral care, hygiene products, and functional beverages and supplements. Revenue is generated through the sale of branded products via supermarkets, pharmacies, convenience stores, and wholesale distributors.
Manufacturing is largely outsourced to third‑party producers, while Genomma Lab retains control over formulation, branding, marketing, and distribution strategy. The company owns and manages a broad portfolio of well‑known brands such as XL‑3, Asepxia, Cicatricure, Tío Nacho, Next, and Suerox. Operations are supported by in‑house marketing, regulatory, and supply‑chain management capabilities, with distribution handled through a mix of direct sales and third‑party logistics partners.
Strategic Position & Investments
Genomma Lab’s strategy centers on expanding its core brands, entering adjacent wellness categories, and increasing penetration in international markets. Growth initiatives include product line extensions, reformulations aligned with regulatory and consumer trends, and increased investment in digital and data‑driven marketing. The company has historically favored organic brand development, complemented by selective acquisitions of established brands that can be scaled through its marketing platform.
Notable investments have focused on strengthening high‑margin dermocosmetic and functional nutrition offerings, as well as optimizing working capital and debt structure following periods of rapid expansion. Genomma Lab continues to invest in emerging self‑care categories, particularly hydration, skin health, and preventive wellness, while maintaining a disciplined approach to capital allocation.
Geographic Footprint
Genomma Lab is headquartered in Mexico, which remains its largest market and operational hub. The company has a significant presence across Latin America, including countries such as Brazil, Argentina, Colombia, Chile, and Peru, where it distributes a localized portfolio of its core brands. International sales represent a substantial portion of total revenue, reflecting the company’s regional diversification strategy.
Beyond Latin America, Genomma Lab operates in the United States and parts of Europe, including Spain and Italy, primarily targeting Hispanic and mass‑market consumer segments. Its products are sold across multiple continents through established retail chains, giving the company broad international reach despite a relatively centralized corporate structure.
Leadership & Governance
Genomma Lab was founded by Rodrigo Herrera Aspra, who continues to play a central role in shaping the company’s strategic direction. The leadership philosophy emphasizes entrepreneurial brand building, rapid execution, and strong marketing discipline, supported by centralized decision‑making and performance oversight.
Key executives include:
- Rodrigo Herrera Aspra – Chairman and Chief Executive Officer
- Javier López – Chief Financial Officer
Publicly available information confirms the leadership role of the founder and CEO; however, detailed confirmation of executive roles beyond the CEO level is data inconclusive based on available public sources.